Close
Close

pMMLV-CAR MUC1 (SM3/HMFG2) h(BBζ) (CAR-MV-01LX295)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Recombinant Moloney murine leukemia virus (MMLV) retroviral vectors serve as efficient viral vector tools for introducing genes permanently into a wide variety of dividing cells, and provide an alternative to modify primary T cells. Creative biolabs has developed retroviral CAR vector pMMLV MUC1 (SM3/HMFG2) h(BBζ), which is constructed for the engineering of T cells to target human MUC1. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-MUC1 antibody linked to CD137 (4-1BB) and CD3-zeta signaling domains. And the vector product was designed for the treatment of Colorectal cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • MUC1
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Colorectal cancer
  • Generation
  • Second
  • Vector Name
  • pMMLV
  • Vector Length
  • ~6kb
  • Vector Type
  • Recombinant Moloney murine leukemia virus (MMLV) retroviral vector
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigennonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric 4-1BB and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • SM3/HMFG2
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • mucin 1, cell surface associated
  • Synonyms
  • EMA; MCD; PEM; PUM; KL-6; MAM6; MCKD; PEMT; CD227; H23AG; MCKD1; MUC-1; ADMCKD; ADMCKD1; CA 15-3; MUC-1/X; MUC1/ZD; MUC-1/SEC; M3A1

Customize Your CAR Products

Customize Your CAR Products
Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data Funcs

Fig.1 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with OME for 6hrs.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.1 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with OME for 6hrs.

Flow cytometry tested the lysis of different tumor cells by CAR-MUC1 T cells and GFP+ T cells, respectively. CAR-MUC1 T and GFP+ T cells were coculture with tumors cell from OME for 6 h.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.2 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with HN4 for 6hrs.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.2 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with HN4 for 6hrs.

Flow cytometry tested the lysis of different tumor cells by CAR-MUC1 T cells and GFP+ T cells, respectively. CAR-MUC1 T and GFP+ T cells were coculture with tumors cell from HN4 for 6 h.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.3 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with CAL33 for 6hrs.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.3 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with CAL33 for 6hrs.

Flow cytometry tested the lysis of different tumor cells by CAR-MUC1 T cells and GFP+ T cells, respectively. CAR-MUC1 T and GFP+ T cells were coculture with tumors cell from CAL33 for 6 h.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.4 IL-2 secretion of CAR-MUC1 T cells and GFP+ T cells in coculture supernatants after different E/T ratio were measured by ELISA assay.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.4 IL-2 secretion of CAR-MUC1 T cells and GFP+ T cells in coculture supernatants after different E/T ratio were measured by ELISA assay.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.5 IFN-γ secretion of CAR-MUC1 T cells and GFP+ T cells in coculture supernatants after different E/T ratio were measured by ELISA assay.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.5 IFN-γ secretion of CAR-MUC1 T cells and GFP+ T cells in coculture supernatants after different E/T ratio were measured by ELISA assay.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.6 TNF-α secretion of CAR-MUC1 T cells and GFP+ T cells in coculture supernatants after different E/T ratio were measured by ELISA assay.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.6 TNF-α secretion of CAR-MUC1 T cells and GFP+ T cells in coculture supernatants after different E/T ratio were measured by ELISA assay.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.7 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with tumor cell after exogenous addition of IL22 recombinant protein.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.7 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with tumor cell after exogenous addition of IL22 recombinant protein.

After 72 h of exogenous addition of IL22 recombinant protein, detected the killing of CAR-MUC1 T cells against OME cell line and different HNSCC cell lines in different E/T ratios.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.8 Cytokine secretion of CAR-MUC1 T cells and GFP+ T cells in coculture supernatants with different E/T ratio after exogenous addition of IL22 addition.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.8 Cytokine secretion of CAR-MUC1 T cells and GFP+ T cells in coculture supernatants with different E/T ratio after exogenous addition of IL22 addition.

After 72 hours of exogenous addition of IL22 recombinant protein, cytokine secretion in coculture supernatants after different E/T ratio were measured by ELISA assay.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.9 Microscopic observation of the ability of two different kinds of CAR-T cells and GFP+T cells to capture cells in 1:2 E/T ratio.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.9 Microscopic observation of the ability of two different kinds of CAR-T cells and GFP+T cells to capture cells in 1:2 E/T ratio.

In CAR-MUC1 T cells group, a little number of CAR-MUC1 T cells agglomerate around tumor cells; In CAR-MUC1-IL22 T cells group, large number of CAR-MUC1-IL22 T cells agglomerate around tumor cells (Red arrow is point to the tumor cell; the blue arrow is point to the T cell or two kinds of CAR-T cells).

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.10 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with tumor cell after for 72 h.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.10 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with tumor cell after for 72 h.

Three different T cells were incubated with tumor cell (Cal33) and non-neoplastic epithelial cell (OME) at a low E/T ratio (1:1; 1:2; 1:5; 1:10) for 72 h,
flow cytometry tested the apoptosis rate of tumor cells.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.11 Representative T-cell expansion profile of three different T cells.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.11 Representative T-cell expansion profile of three different T cells.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.12 ELISA detected the secretion of IL22 in the culture supernatant.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.12 ELISA detected the secretion of IL22 in the culture supernatant.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.13 ELISA detected the secretion of IL22 in the coculture supernatant of different E/T ratio.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.13 ELISA detected the secretion of IL22 in the coculture supernatant of different E/T ratio.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.14 ELISA detected the secretion of IL-2/IFN-γ/TNF-α in the coculture supernatant of low E/T ratio.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.14 ELISA detected the secretion of IL-2/IFN-γ/TNF-α in the coculture supernatant of low E/T ratio.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.15 CAR-T cells induce tumor degradation of HNSCC in vivo.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.15 CAR-T cells induce tumor degradation of HNSCC in vivo.

1E6 fLuc+ HN4 tumor cells were injected into the subcutaneous tissue in NSG mouse. After 10 d, tail intravenous injection of CAR T cells (n = 5). The mice were sacrificed on day 40 for tumor analysis. B, Bioluminescence images of four treatment groups mice.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.16 CAR-T cells induce tumor degradation of HNSCC in vivo.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.16 CAR-T cells induce tumor degradation of HNSCC in vivo.

Total body bioluminescence units quantitate were measured by bioluminescence photometry and flux values (photons per second, P < .001).

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.17 CAR-T cells induce tumor degradation of HNSCC in vivo.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.17 CAR-T cells induce tumor degradation of HNSCC in vivo.

Tumor volume growth curves of four treatment groups (P < .001).

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.18 CAR-T cells induce tumor degradation of HNSCC in vivo.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.18 CAR-T cells induce tumor degradation of HNSCC in vivo.

T-cell infiltration statistics in four treatment groups (P < .01).

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.
Complete CAR data Funcs

Fig.19 CAR-T cells induce tumor degradation of HNSCC in vivo.

CAR Construction : SM3/HMFG2 scfv-41BB-CD3ζ-IL22 Latest CAR Construction

Fig.19 CAR-T cells induce tumor degradation of HNSCC in vivo.

CD3 in tumor tissue was detected using the anti-CD3 antibody (Abcam 5690, dilution 1:200); cell nuclei were stained with DAPI.

Mei, Z., Zhang, K., Lam, A. K. Y., Huang, J., Qiu, F., Qiao, B., & Zhang, Y. (2020). MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer medicine, 9(2), 640-652.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-MUC1 (SM3/HMFG2) h(41BB-CD3ζ) CAR, pMMLV (CAR-MV-01LX295). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

CAR Vector Products

CAR Cell Products

CAR mRNA

CAR Viral Particles

CAR-MA Cell Products

AbTCR Vector Products

CAR-MA Vector Products

TriCAR Vector Products

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout